ArriVent BioPharma Appoints Brent Rice as Chief Commercial Officer to Lead Firmonertinib Commercialization
核心洞察
ArriVent BioPharma has appointed Brent S. Rice as Chief Commercial Officer, bringing over 25 years of biotechnology and pharmaceutical commercial experience to the clinical-stage company.
Rice previously served as global Chief Commercial Officer at Autolus Therapeutics, where he successfully transitioned the company from clinical-stage to commercial operations and led the launch of their first commercial product.
The appointment comes as ArriVent's lead candidate firmonertinib (搜索) approaches potential approval for EGFR (搜索) mutant non-small cell lung cancer (搜索), with the company also developing a pipeline of antibody drug conjugates.
ArriVent BioPharma announced the appointment of Brent S. Rice as Chief Commercial Officer on September 22, 2025, as the clinical-stage biopharmaceutical company prepares for the potential commercialization of its lead drug candidate firmonertinib (搜索) for EGFR (搜索) mutant non-small cell lung cancer (搜索) (NSCLC (搜索)).
Rice brings over 25 years of U.S. and global commercial experience in the biotechnology and pharmaceutical industry to his new role at the Nasdaq-listed company (AVBP). His appointment comes at what CEO Bing Yao described as "a pivotal stage of our growth" as firmonertinib (搜索) nears potential regulatory approval.
Strategic Leadership for Commercial Transition
"Brent brings a proven track record in launching novel therapies, building high-performing organizations, and leading strategic pipeline planning," said Bing Yao, Chairman and Chief Executive Officer of ArriVent. "We believe his executive leadership experience will position us for success as firmonertinib (搜索) nears potential approval and commercialization for EGFR (搜索) mutant non-small cell lung cancer (搜索) (NSCLC (搜索)), and as we begin to unlock the potential of our ADC portfolio."
Rice's most recent role was as Senior Vice President and global Chief Commercial Officer, and Managing Director U.S. at Autolus Therapeutics Ltd., where he led global commercialization, commercial strategy and business portfolio management of their early and late-stage pipeline of next generation therapies. Under his leadership, Autolus transitioned from a clinical stage development company to a commercial organization, where he built the U.S. organization and led the successful introduction and launch of Autolus' first commercial product.
Extensive Industry Experience
Prior to Autolus, Rice held key positions at established pharmaceutical companies, including leading Managed Markets at Juno Therapeutics (搜索), where he developed payer and reimbursement strategy capabilities. He spent 18 years at Amgen in roles of increasing responsibility, earning recognition as a strong cross-functional leader driving innovative partnerships and portfolio success.
Rice brings cross-functional expertise in marketing, operations, and reimbursement, along with experience in building scalable commercial organizations, leading product launches, and negotiating high-value agreements that improve patient access.
Pipeline Focus on Oncology
"ArriVent has built a robust and science-driven pipeline that targets challenging and underserved areas in oncology," Rice said. "I look forward to partnering with the team to build a strong commercial foundation that drives growth and ensures patients access."
ArriVent is a clinical-stage biopharmaceutical company dedicated to the identification, development, and commercialization of differentiated medicines to address the unmet medical needs of patients with cancers. The company seeks to utilize its team's deep drug development experience to maximize the potential of its lead development candidate, firmonertinib (搜索), and advance a pipeline of novel therapeutics, such as next-generation antibody drug conjugates, through approval and commercialization.
Regulatory Milestones Ahead
The company is anticipating top-line pivotal Phase 3 data for firmonertinib (搜索) in previously untreated NSCLC (搜索) patients whose tumors contain EGFR (搜索) exon 20 insertion mutations. The timing of potential approval of firmonertinib for commercialization by health authorities represents a key milestone for the company's transition from clinical-stage development to commercial operations.